Preoperative Use and Discontinuation of Traditional Chinese Herbal Medicine and Dietary Supplements in Taiwan: A Cross-Sectional Questionnaire Survey.
Te-Chun YehShung-Tai HoChe-Hao HsuJu-O WangSenyeong KaoYi-Chang SuSunny Jui-Shan LinHuei-Han LiouTso-Chou LinPublished in: Healthcare (Basel, Switzerland) (2023)
Traditional Chinese herbal medicine has widespread use in Taiwan. This cross-sectional questionnaire survey investigates the preoperative use and discontinuation of Chinese herbal medicine and dietary supplements among Taiwanese patients. We obtained the types, frequency, and sources of Chinese herbal remedies and supplements used. Among 1428 presurgical patients, 727 (50.9%) and 977 (68.4%) reported the use of traditional Chinese herbal medicine and supplements in the past one month, respectively. Only 17.5% of the 727 patients stated discontinuation of herbal remedies 4.7 ± 5.1 (1-24) days before the surgery, and 36.2% took traditional Chinese herbal medicine with concomitant physician-prescribed Western medicine for their underlying diseases. The most commonly used Chinese herbs are goji berry ( Lycium barbarum ) (62.9%) and Si-Shen-Tang (48.1%) in single and compound forms, respectively. The presurgical use of traditional Chinese herbal medicine was common in patients undergoing gynecologic (68.6%) surgery or diagnosed with asthma (60.8%). Women and those with a high household income had a greater tendency to use herbal remedies. This study demonstrates the high proportion of the presurgical use of Chinese herbal remedies and supplements along with physician-prescribed Western medicine in Taiwan. Surgeons and anesthesiologists should be aware of the potential adverse effects of drug-herb interaction for Chinese patients.
Keyphrases
- cross sectional
- end stage renal disease
- patients undergoing
- ejection fraction
- newly diagnosed
- primary care
- emergency department
- chronic kidney disease
- type diabetes
- patient reported
- polycystic ovary syndrome
- coronary artery disease
- physical activity
- acute coronary syndrome
- percutaneous coronary intervention
- quality improvement
- metabolic syndrome
- cystic fibrosis
- risk assessment
- coronary artery bypass
- atrial fibrillation